In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment right until illness progression or even the participants are unable to tolerate the study drugs. Ubiquitin-associated proteins that control The steadiness of critical super enhancer-mediated proteins have https://buzzx232pbl5.ageeksblog.com/profile